Flynn James E bought Larimar Therapeutics ($LRMR) shares on the open market seven times over the past year, totaling $55 million, with his most recent purchase on February 27, 2026. This ranks him 22nd among nearly 5,000 individual insiders, far exceeding the average of $1.5 million across 3.3 transactions.
He sold ARS Pharmaceuticals ($SPRY) shares twice for $13.7 million, most recently on June 27, 2025, ranking 903rd in sales volume. He also sold Nuvalent ($NUVL) shares twice for $70.9 million, most recently on November 24, 2025, placing 224th among nearly 12,000 insiders, well above the $8.6 million average over 6.4 transactions.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 27, 2026 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 1084010 | $5.00 | 35,606,974.0000 | 85,590,392 | 3.14% | 1.27% |
| Feb. 27, 2026 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 1084012 | $5.00 | 35,606,974.0000 | 85,590,392 | 3.14% | 1.27% |
| Feb. 27, 2026 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 831978 | $5.00 | 35,606,974.0000 | 85,590,392 | 2.39% | 0.97% |
| Feb. 27, 2026 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 2000000 | $5.00 | 35,606,974.0000 | 85,590,392 | 5.95% | 2.34% |
| Nov. 24, 2025 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | S | Class A Common Stock | 371287 | $95.45 | 17,248,450.0000 | 72,143,466 | 2.11% | 0.51% |
| Nov. 24, 2025 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | S | Class A Common Stock | 371287 | $95.45 | 17,248,450.0000 | 72,143,466 | 2.11% | 0.51% |
| July 31, 2025 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 3387529 | $3.20 | 30,606,974.0000 | 63,815,065 | 12.45% | 5.31% |
| July 31, 2025 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 2599932 | $3.20 | 30,606,974.0000 | 63,815,065 | 9.28% | 4.07% |
| July 31, 2025 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 3387539 | $3.20 | 30,606,974.0000 | 63,815,065 | 12.45% | 5.31% |
| June 27, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 370074 | $18.46 | 9,774,508.0000 | 102,390,828 | 3.65% | 0.36% |
| June 27, 2025 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 370075 | $18.46 | 9,774,508.0000 | 102,390,828 | 3.65% | 0.36% |
| June 18, 2025 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Class A Common Stock | 2647 | $0.00 | 17,998,669.0000 | 66,408,807 | 0.01% | 0.00% |
| June 18, 2025 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Stock Option (Right to Buy) | 4147 | $0.00 | 4,147.0000 | 66,408,807 | 9999.99% | 0.01% |
| June 18, 2025 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Class A Common Stock | 2647 | $0.00 | 17,998,669.0000 | 66,408,807 | 0.01% | 0.00% |
| June 18, 2025 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Stock Option (Right to Buy) | 4147 | $0.00 | 4,147.0000 | 66,408,807 | 9999.99% | 0.01% |
| May 13, 2025 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | A | Stock Option (Right to Buy) | 19000 | $0.00 | 19,000.0000 | 63,815,065 | 9999.99% | 0.03% |
| April 21, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 1611864 | $0.00 | 3,223,728.0000 | 23,103,105 | 100.00% | 6.98% |
| April 21, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 1611864 | $0.00 | 3,223,728.0000 | 23,103,105 | 100.00% | 6.98% |
| April 14, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Stock Option (Right to Buy) | 17600 | $0.00 | 17,600.0000 | 23,103,105 | 9999.99% | 0.08% |
| Feb. 27, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Warrants | 1611863 | $0.00 | 1,664,251.0000 | 757,749 | 49.20% | 100.00% |
| Feb. 27, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 1258614 | $0.00 | 2,517,228.0000 | 757,749 | 100.00% | 100.00% |
| Feb. 27, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Warrants | 1611863 | $0.00 | 1,664,251.0000 | 757,749 | 49.20% | 100.00% |
| Feb. 27, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Common Stock | 353249 | $0.93 | 2,494,108.0000 | 757,749 | 16.50% | 46.62% |
| Feb. 27, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 1258614 | $0.00 | 2,517,228.0000 | 757,749 | 100.00% | 100.00% |
| Feb. 27, 2025 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Common Stock | 353249 | $0.93 | 2,494,108.0000 | 757,749 | 16.50% | 46.62% |
| Jan. 27, 2025 | Acutus Medical, Inc. | $AFIB | Flynn James E | Not found | D | Warrant to Purchase Common Stock | 209996 | $0.00 | 0.0000 | 29,912,305 | 100.00% | 0.70% |
| Jan. 27, 2025 | Acutus Medical, Inc. | $AFIB | Flynn James E | Not found | D | Warrant to Purchase Common Stock | 1889509 | $0.00 | 0.0000 | 29,912,305 | 100.00% | 6.32% |
| Jan. 27, 2025 | Acutus Medical, Inc. | $AFIB | Flynn James E | Not found | D | Warrant to Purchase Common Stock | 1889509 | $0.00 | 0.0000 | 29,912,305 | 100.00% | 6.32% |
| Jan. 27, 2025 | Acutus Medical, Inc. | $AFIB | Flynn James E | Not found | D | Warrant to Purchase Common Stock | 193002 | $0.00 | 0.0000 | 29,912,305 | 100.00% | 0.65% |
| Jan. 27, 2025 | Acutus Medical, Inc. | $AFIB | Flynn James E | Not found | D | Warrant to Purchase Common Stock | 31116 | $0.00 | 0.0000 | 29,912,305 | 100.00% | 0.10% |
| Nov. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 9553 | $17.77 | 10,514,657.0000 | 97,032,331 | 0.09% | 0.01% |
| Nov. 11, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 40596 | $17.45 | 10,755,696.0000 | 97,032,331 | 0.38% | 0.04% |
| Nov. 11, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 40596 | $17.45 | 10,755,696.0000 | 97,032,331 | 0.38% | 0.04% |
| Nov. 11, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 223632 | $18.15 | 10,532,064.0000 | 97,032,331 | 2.08% | 0.23% |
| Nov. 11, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 223632 | $18.15 | 10,532,064.0000 | 97,032,331 | 2.08% | 0.23% |
| Nov. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 7853 | $17.16 | 10,524,211.0000 | 97,032,331 | 0.07% | 0.01% |
| Nov. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 7854 | $17.16 | 10,524,210.0000 | 97,032,331 | 0.07% | 0.01% |
| Nov. 12, 2024 | ARS Pharmaceuticals, Inc. | $SPRY | Flynn James E | TenPercentOwner | S | Class A Common Stock | 9554 | $17.77 | 10,514,657.0000 | 97,032,331 | 0.09% | 0.01% |
| Oct. 22, 2024 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | S | Class A Common Stock | 1000000 | $97.75 | 17,991,024.0000 | 65,678,693 | 5.27% | 1.52% |
| Oct. 22, 2024 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | S | Class A Common Stock | 1000000 | $97.75 | 17,991,024.0000 | 65,678,693 | 5.27% | 1.52% |
| Sept. 17, 2024 | Bicara Therapeutics Inc. | $BCAX | Flynn James E | Other | C | Series C Preferred Stock | 7973325 | $0.00 | 0.0000 | 580,109,000 | 100.00% | 1.37% |
| Sept. 17, 2024 | Bicara Therapeutics Inc. | $BCAX | Flynn James E | Other | P | Common Stock | 35000 | $18.00 | 1,795,174.0000 | 580,109,000 | 1.99% | 0.01% |
| Sept. 17, 2024 | Bicara Therapeutics Inc. | $BCAX | Flynn James E | Other | P | Common Stock | 35000 | $18.00 | 1,795,174.0000 | 580,109,000 | 1.99% | 0.01% |
| Sept. 17, 2024 | Bicara Therapeutics Inc. | $BCAX | Flynn James E | Other | C | Common Stock | 862587 | $0.00 | 1,760,174.0000 | 580,109,000 | 96.10% | 0.15% |
| Sept. 17, 2024 | Bicara Therapeutics Inc. | $BCAX | Flynn James E | Other | C | Common Stock | 862587 | $0.00 | 1,760,174.0000 | 580,109,000 | 96.10% | 0.15% |
| Sept. 17, 2024 | Bicara Therapeutics Inc. | $BCAX | Flynn James E | Other | C | Series C Preferred Stock | 7973325 | $0.00 | 0.0000 | 580,109,000 | 100.00% | 1.37% |
| July 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Common Stock | 5883000 | $0.00 | 17,876,098.0000 | 10,750,194 | 49.05% | 54.73% |
| July 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Common Stock | 5883000 | $0.00 | 17,876,098.0000 | 10,750,194 | 49.05% | 54.73% |
| July 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Series X Non-Voting Convertible Preferred Stock | 5883 | $0.00 | 95,914.0000 | 10,750,194 | 5.78% | 0.05% |
| July 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | M | Series X Non-Voting Convertible Preferred Stock | 5883 | $0.00 | 95,914.0000 | 10,750,194 | 5.78% | 0.05% |
| July 11, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Stock Option (Right to Buy) | 264000 | $0.00 | 264,000.0000 | 10,750,194 | 9999.99% | 2.46% |
| July 9, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 722175 | $0.00 | 20,897,175.0000 | 10,750,194 | 3.58% | 6.72% |
| July 9, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 20175000 | $0.00 | 40,350,000.0000 | 10,750,194 | 100.00% | 100.00% |
| July 9, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 20175000 | $0.00 | 40,350,000.0000 | 10,750,194 | 100.00% | 100.00% |
| July 9, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Warrants | 722175 | $0.00 | 20,897,175.0000 | 10,750,194 | 3.58% | 6.72% |
| June 12, 2024 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Stock Option (Right to Buy) | 3789 | $0.00 | 3,789.0000 | 58,223,339 | 9999.99% | 0.01% |
| June 12, 2024 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Stock Option (Right to Buy) | 3789 | $0.00 | 3,789.0000 | 58,223,339 | 9999.99% | 0.01% |
| June 12, 2024 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Class A Common Stock | 2499 | $0.00 | 19,993,523.0000 | 58,223,339 | 0.01% | 0.00% |
| June 12, 2024 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Class A Common Stock | 2499 | $0.00 | 19,993,523.0000 | 58,223,339 | 0.01% | 0.00% |
| May 29, 2024 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | A | Stock Option (Right to Buy) | 19000 | $0.00 | 19,000.0000 | 43,909,069 | 9999.99% | 0.04% |
| March 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Common Stock | 3055049 | $0.00 | 6,110,098.0000 | 5,133,093 | 100.00% | 59.52% |
| March 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 40350 | $0.00 | 107,680.0000 | 5,133,093 | 59.93% | 0.79% |
| March 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 40350 | $0.00 | 107,680.0000 | 5,133,093 | 59.93% | 0.79% |
| March 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 13490 | $0.00 | 67,330.0000 | 5,133,093 | 25.06% | 0.26% |
| March 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Series X Non-Voting Convertible Preferred Stock | 13490 | $0.00 | 67,330.0000 | 5,133,093 | 25.06% | 0.26% |
| March 15, 2024 | BiomX Inc. | $PHGE | Flynn James E | Other | A | Common Stock | 3055049 | $0.00 | 6,110,098.0000 | 5,133,093 | 100.00% | 59.52% |
| March 12, 2024 | AdaptHealth Corp. | $AHCO | Flynn James E | Other | S | Class A Common Stock | 114906 | $10.70 | 13,257,940.0000 | 134,418,000 | 0.86% | 0.09% |
| March 11, 2024 | AdaptHealth Corp. | $AHCO | Flynn James E | Other | S | Class A Common Stock | 88040 | $11.13 | 13,372,846.0000 | 134,418,000 | 0.65% | 0.07% |
| March 11, 2024 | AdaptHealth Corp. | $AHCO | Flynn James E | Other | S | Class A Common Stock | 94567 | $10.92 | 13,460,886.0000 | 134,418,000 | 0.70% | 0.07% |
| March 8, 2024 | AdaptHealth Corp. | $AHCO | Flynn James E | Other | S | Class A Common Stock | 4495 | $11.03 | 13,555,453.0000 | 134,418,000 | 0.03% | 0.00% |
| March 8, 2024 | AdaptHealth Corp. | $AHCO | Flynn James E | Other | S | Class A Common Stock | 47992 | $10.92 | 13,559,948.0000 | 134,418,000 | 0.35% | 0.04% |
| Feb. 16, 2024 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 1430205 | $8.74 | 21,231,974.0000 | 43,909,069 | 7.22% | 3.26% |
| Feb. 16, 2024 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 1430206 | $8.74 | 21,231,974.0000 | 43,909,069 | 7.22% | 3.26% |
| Feb. 16, 2024 | Larimar Therapeutics, Inc. | $LRMR | Flynn James E | Other | P | Common Stock | 1430206 | $8.74 | 21,231,974.0000 | 43,909,069 | 7.22% | 3.26% |
| Feb. 6, 2024 | FRACTYL HEALTH, INC. | $GUTS | Flynn James E | Other | C | Common Stock | 757548 | $0.00 | 757,548.0000 | 0 | 9999.99% | 0.00% |
| Feb. 6, 2024 | FRACTYL HEALTH, INC. | $GUTS | Flynn James E | Other | C | Common Stock | 76706 | $0.00 | 834,254.0000 | 0 | 10.13% | 0.00% |
| Feb. 6, 2024 | FRACTYL HEALTH, INC. | $GUTS | Flynn James E | Other | C | Series C-2 Preferred Stock | 1625699 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Feb. 6, 2024 | FRACTYL HEALTH, INC. | $GUTS | Flynn James E | Other | C | Series D Preferred Stock | 164612 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| June 15, 2023 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 49,668,864 | 9999.99% | 0.03% |
| June 15, 2023 | Nuvalent, Inc. | $NUVL | Flynn James E | Other | A | Stock Option (Right to Buy) | 15000 | $0.00 | 15,000.0000 | 49,668,864 | 9999.99% | 0.03% |